Physician profile
Keith Lashinski
NPI 1952736472
$1,977.92
in general payments reported to CMS, 2019-2025
18 companies · $556 in 2025
The $556 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $224 · 2023: $411 · 2024: $596 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $414.51 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $287.86 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.50 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $195.48 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $134.68 | 2022-2025 | |
| Abiomed | $84.60 | 2024-2025 | Impella |
| Scpharmaceuticals INC. | $82.50 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.39 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.63 | 2023-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $77.57 | 2023-2025 | Verquvo |
| Novo Nordisk INC | $76.62 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Baxter Healthcare | $68.20 | 2022 | |
| Medtronic, INC. | $40.12 | 2021-2024 | Linq II |
| Philips North America LLC | $35.83 | 2024 | (Ck7) Extended Holter |
| Bridgebio Pharma, INC. | $34.05 | 2025 | Attruby |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.25 | 2023 | Lifevest |
| Boston Scientific Corporation | $20.84 | 2022 | |
| Esperion Therapeutics, INC. | $15.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lashinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.